Biological
Efineptakin alfa
Efineptakin alfa is a biological therapy with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 33.3%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
2(40%)
Results Posted
100%(1 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
active_not_recruiting120%
completed120%
recruiting120%
terminated240%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_2
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05465954
completedphase_1
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NCT05075603
terminatedphase_1
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
NCT04588038
terminatedphase_1
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
NCT04893018
active_not_recruitingphase_2
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811
Clinical Trials (5)
Showing 5 of 5 trials
NCT05465954Phase 2
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05075603Phase 1
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NCT04588038Phase 1
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
NCT04893018Phase 1
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
NCT04984811Phase 2
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5